Givastomig, a CLDN18.2 x 4-1BB bispecific antibody, continues to show robust efficacy when combined with nivolumab and ...
Enhertu (trastuzumab deruxtecan) has now been approved in China for the treatment of adult patients with unresectable or ...
Daiichi Sankyo &AstraZeneca’s Enhertu approved in China as first HER2 directed medicine for patients with HER2 low or HER2 ultralow metastatic breast cancer ...
We independently review everything we recommend. We may get paid to link out to retailer sites, and when you buy through our links, we may earn a commission. Learn more› By Hannah Frye Hannah Frye is ...
Claudin18.2 is a subtype of the Claudin18 tight junction protein family, found on the surface of cell membranes. Under normal conditions, its expression is limited to low levels in differentiated ...
Digital Pathology: The biotech company Roche is receiving support towards its efforts to advance cancer diagnosis, as the U.S. Food and Drug Administration (FDA) granted Breakthrough Device ...
Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with artificial-intelligence-powered analysis to provide what the company says could become ...
The FDA expanded the approval of trastuzumab deruxtecan (T-DXd, Enhertu) to include treatment of unresectable/metastatic hormone receptor (HR)-positive, HER2-low ...
The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer, based on phase 3 DESTINY-Breast06 trial results. The FDA has granted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback